verticals. Thank you, three Joe. core In into XXXX, we our reorganized business
to to human progress, we have approach have listened business I like focused be structured significant We shareholders each vertical. development. and our where our begin today's to to made also that, and with call health, results in scientifically both and have would With on
cell lines durability. fiscal of for to comparable objective to Our to XXXX Phase CX-produced enhanced better safety proteins design for protein in-human year efficacy trial efficacy a and primary by X first those produced traditional our initiate vaccine CX-produced were to demonstrate further of and biomolecules and scientific
We X clinical dosing objectives DYAI-XXX, Phase announced recently has trial completed candidate. as a booster for met a vaccine those we COVID-XX the for been
mentioned, protein Joe ready protein production of platform CX As recombinant for vaccines. fully commercialization is our
have for data complex of CX-produced partners of potential cell vaccine lines of is equal quality. are to their those antigens platform producing addition quantities demonstrated We for efficiently. previously criterion data CX evaluation is unparalleled provides that that rapidly capable first-in-human The a protein or Similarly, in targets. the to in of other imperative commercialization proteins a terms it line for cell CX utilize produced expressed when by choosing superior that critical
third-party many between -- monoclonal have and great expressed which how activity and we multiple release, parties, demonstrated assayed assays number press how In mining third antibodies, that mAbs. CX-produced today's mAbs who CHO-produced a of we by we the neutralizing reported shared similarity
COVID-XX cell standards non-human for monoclonal safety development. produce clinical primate this and ensure third quarter, products is select regulatory for have a their comparability As Again, in potential lines as partners our of comparator monoclonal we the the profile a to the critical study, completed to antibody. commercial they required their to antibodies CX-produced equality reported showing one and targets co-produced to
are designing This mAb biomolecules. better focused year, we also on
to have conjugating proteins, antigens complex ferritin as such CX nanoparticles. express We cells developed and
targeting vaccine AMHCX antigen several developed included antigens that efficacy increase COVID-XX to domain influenza trimerization we durability. Additionally, and and a and an
our and release, we partners University we HXNX and in range being advancements that longer-lasting biomolecules a Virovax, of also seen effective flu relevant as are where with may trials. as enable potentially have of CX-produced known such the you vaccines develop Oslo commonly that like and wide In bird other the new and or infectious these animal across adjuvants are its diseases. have targeting better HXNX today's diseases more testing Dyadic and to and These with in antigens systems partners used
and Africa companies We and vaccine partnerships clinical candidate, continue commercial and to development in countries DYAI-XXX well as pharmaceutical focus one Hengrui, advancing leading products our as Pharmaceuticals; with longer-term Epogen the China; with largest COVID-XX Janssen the and Health developing in Rubic collaboration India. of our like with of on strategic of pharmaceutical partners One
certain an like equity use In expect provides done Alphazyme, an to BDI to upfront of and who such companies we of sale generate afford cash pay from a the have fee. XXXX. these our successfully opportunity QX cases, of This and us smaller to with we technology our with access case equity generated as to was million with can't the leader, the cash. in obtain Alphazyme $X.XX BDI two positions in in total Note, stakes XXXX sale equity
receive into XXXX. Additionally, have and agreements new to continue potential sales in anticipate entering that based Alphazyme. milestone and on we by products license royalty we of payments will We CX-expressed pharmaceutical the expanding
with high payout shorter smaller However, lines, core the and adjusting human in costs less our market other order health revenue, verticals partnerships and to approval need to focus we're and development with among obstacles market products to acceptance. commercialization unmet time to and accelerate
disease, grades this due over an a points market for health. reagent and segment, price these at is is of of $X.X is X% serum In projects. product An of used in in but development currently markets. developed and across R&D. only global tool billion a markets vaccines approximately growing human are as serum and many year argument as is in not a to animal our albumin being Pharmaceutical The albumin diagnostic potential serum of different common focus across the a There treatment use increased example albumin the a recombinant market, multiple
production to is the with used an term. at Joe albumin and Dyadic how to animal-free for media Dyadic product potential produce Later, providing in serum due shorter microbial alternative as back in systems. proteins has and to our share significantly albumin be opportunity well, highly And a competitive being commercialization serum will productive price platforms low-cost
therapeutic issued research enzyme active billion we being global a XXXX, a diagnostic, In a uses of the potentially vein, that similar part non-yeast poster in the and enzymes. the for market first CYPXXX CYPXXX to cell $XX enzymes produce publication product enzyme. are showed of an development
is enhance years, a pharmaceutical we or for specifically drug challenge small strategy near-term industry, biologics and diagnostics to that protein the has our institution. another chiral corporate of of enzymes with the for vaccines an is synthesis in our for opportunity uses. This to As example risen molecules, other collaboration and a academic production that high required of from discussed several the yield adheres major near-term
more we the trials today, at dozen announced last and vaccine late a development, than been have As animal Dyadic that forefront is carried of half year alone. out
additional, animal In HXNX, scheduled infectious are are diseases. other ongoing the with influenza, and bird's example, antigens; bird and trials flu; CX-produced for
and effective protein Our commercialization for is and are platform recombinant vaccine to vaccines. and/or collaborators better opportunities. produce ready durable CX our we more working fully And developing biomolecules
shorter-term and on In opportunities product objectives, cost refined risk our less a associated that commercialization focus health have development. time, XXXX, with we've human include
discussions engaged licensing negotiations will these also pursuing value. to currently and greater help by products license platform drive that that the with pharmaceutical meet CX larger scope are in can long-term our objectives We partners and agreements
for In and What margin global leveraging operate that animal in health, health the chain verticals. health turn and I would and animal makes between impact the markets have are the therapeutic an supply animal segment vaccines across human of we potentially on similarities market the for many attention proteins, this science our is attractive needs there core and as our like human these Dyadic and health. are significant to can sensitivity
others not also impact has supply in and we response prices but eggs markets that it decreased the with an FDA decreased, global or availability as And store, poultry as and CX impact animal reduces humans platform production the a chain pandemic of but to in The for on be believe production. solution well. as ripple not why global vaccine is up ongoing This production can avian just other egg production egg such health. only outbreak flu drove the immense the
had last very antigens can rapidly We potential infectious of antigen. level Late production year, and a that cost, CX at liter per platform of antigen low we we for pandemic a stockpiling. livestock for of record XX grams achieved announced response quantities making preparedness a disease produce large or
human Food animal revenue. joint for of segment is makes vertical terms an collaborator, one proteins area agreement great market. rapidly significant Dyadic products pursuits. health vertical and and holds require this third departure and promise in we particularly is growing that by future of resources Our not anchored this dedicating which existing our for potential opportunity for Ingredients Dyadic is This our of believe excitement development and fully-funded with support and alternative Global near-term this is our does What within interesting a and exploiting
in for manufacture Dyadic applications food, platform, non-pharmaceutical nutrition, expression and biological enable further has and fulfillment launched health and is Dapibus gene designed customized its fungal-based production to as rapid use large-scale other platform, development microbial products metabolites and protein which enzymes, and wellness. of proteins, a is low-cost the such
and the this for potential been maximize opportunity Joe? he our value building the and will to Joe proposition and out segment, describe efforts alternative in strategy has proteins.
